UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
------------------
For the month of August 2004
Commission File Number: 001-31368
SANOFI-SYNTHELABO
(Translation of registrant's name into English)
174, avenue de France, 75013 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): _____
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): _____
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the information to
the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
Yes [ ] No [X]
If "Yes" marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 82-________
This Report on Form 6-K shall be deemed to be incorporated by reference
into Sanofi-Synthelabo's Registration Statement on Form F-4 (Registration No.
333-112314), as post-effectively amended and declared effective on May 13, 2004
by the United States Securities Exchange Commission, and the related prospectus,
dated April 9, 2004, and the prospectus supplement, dated May 27, 2004, each
filed pursuant to Rule 424(b) under the United States Securities Act of 1933, as
amended, and shall be part thereof from the date on which this Report is filed,
to the extent not superseded by documents or reports subsequently filed or
furnished.
[SANOFI-SYNTHELABO LOGO]
[GRAPHIC] Investor Relations
Paris, August 19th, 2004
Dear Madam, Dear Sir,
A CONFERENCE CALL for financial analysts, institutional investors and
journalists will be organized on TUESDAY, AUGUST 31ST, 2004 AT 3.00 P.M.
(Paris time) to present 2004 HALF-YEAR RESULTS, and INTERIM CLINICAL DATA
(RIO-EUROPE ONE-YEAR DATA) OF ACOMPLIA (TM) IN OBESITY. This conference
will be held in English.
In order to participate in the conference call, the following numbers are
to be dialed 10 minutes before it starts :
FRANCE : 00 33 (0) 1 70 70 60 60 CODE : 902488
UNITED KINGDOM : 44 (0) 20 7784 10 04 CODE : 902488
USA : 1 718 354 11 52 CODE : 902488
The slides will be available on our website (www.sanofi-synthelabo.com) on
Tuesday, August 31st from 10:00 a.m.
This conference will be broadcast live on our website
No recorded version will be archived for this conference.
Yours sincerely,
Philippe Goupit
INVESTOR RELATIONS DEPARTMENT
Philippe Goupit Director of Investor Relations
Arnaud Delepine Investor Relations Europe
Sanjay Gupta Investor Relations US
Anne d'Halluin-Sulzer Investor Relations
Loic Gonnet Investor Relations
CONTACTS:
E-mail: investor-relations@sanofi-synthelabo.com
Europe US
Tel: + 33 1 53 77 45 45 Tel.: + 1 212 551 40 18
Fax: + 33 1 53 77 42 96 Fax: + 1 646 487 40 18
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Dated: August 19, 2004 SANOFI-SYNTHELABO
By: /s/ Marie-Helene Laimay
-------------------------------------
Name: Marie-Helene Laimay
Title: Senior Vice President and
Chief Financial Officer